One tradition of Contact Lens Spectrum is to report an "Event of the Year"—something that stands out in the field of contact lenses occurring in 2018 that deserves special attention and recognition. It’s also traditional for us to solicit nominations for this event from our readership. If you have a nomination for this year’s "Event," let us know by emailing me directly at email@example.com.
Jason J. Nichols, OD, MPH, PhD
Euclid Systems Corporation Appoints David Bland as Vice President of U.S. Sales
Euclid Systems Corporation announced the appointment of David Bland as the new vice president of sales. Effective Oct. 30, Mr. Bland will lead the company’s U.S. sales efforts to assist eyecare professionals with expanding their practices through orthokeratology in the field of myopia management. His primary responsibilities will include strengthening customer partnerships, launching new products and programs, and executing strategic initiatives in the United States.
He joins Euclid Systems Corporation from Bausch + Lomb, where he held a leadership role in the Specialty Vision Products business unit. Mr. Bland brings more than 30 years of experience in specialty eye care, leadership, business strategy, and building high performance teams.
ABB Optical Group Donates $14,000 through Fifth Annual ABB Cares Program
ABB Optical Group announced that seven non-profit organizations, nominated by eyecare professionals nationwide, will receive grants ranging from $1,000 to $5,000 for outstanding programming and community impact through the Fifth Annual ABB Cares Program.
A platinum ABB Cares grant of $5,000 went to Extra Special People, Inc. Gold ABB Cares grants of $2,500 went to Santa Maria Hostel, Inc., and Virginia B. Andes Volunteer Community Clinic. Silver ABB Cares grants of $1,000 went to Alameda Education Foundation, Global Glimpse, Special Kids Connect, and Interfaith Outreach. For more information about these ABB Cares recipients, visit https://www.abboptical.com/about-us/pressroom/10_29_2018.
Ampleye Now Featuring Aberration Correcting Optics
Art Optical announced that its Ampleye scleral lens design now features advanced aberration correcting optics. This fully-automated, anterior surface technology neutralizes the unwanted plus or minus power inherently present in the optical zone of the lens to deliver a consistent power profile, according to the company. Ampleye’s aberration correcting technology is a result of Art Optical’s ongoing collaboration with Pacific University.
As a full-featured scleral design, Ampleye is fit diagnostically with the aid of a nine-lens fitting set. Prescription lenses are available in diameters from 15.0mm to 17.0mm, and design options include anterior-surface toric and multifocal optics, quadrant-specific control technology, and Tangible Hydra-PEG (Tangible Science) surface coating on lenses made in Optimum (Contamac) materials. Additionally, Ampleye is FDA-indicated for the management of dry eye and ocular surface disease.
Eyevance Acquires Flarex in the United States
Eyevance Pharmaceuticals announced the acquisition of Flarex (fluorometholone acetate ophthalmic suspension) 0.1% from Novartis AG. U.S. Food and Drug Administration-approved Flarex is indicated for the treatment of steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the eye.
Rev360 Announces Scott Filion as President and COO
Rev360 welcomed Scott Filion as president and COO. With more than 25 years of experience in leadership roles at GE Healthcare Information Technologies and GE Medical system, EMC Healthcare, Hosting, and GetWellNetwork, Mr. Filion will assume day-to-day operations of the company. He has also been tapped to transition into the role of CEO in 2019, as founder and CEO Dr. Scott Jens will move to a senior advisor position on the Rev360 board of directors.
Scott Filion is a member of the Healthcare Information and Management Systems Society (HIMSS) and the College of Healthcare Information Management Executives (CHIME). In addition, he has served as an advisor and board member on multiple Health IT companies and community organizations.
Essilor Appoints Kovin Naidoo Senior Vice President of Inclusive Business, Philanthropy and Social Impact
Essilor announced the appointment of Professor Kovin Naidoo as senior vice president of Inclusive Business, Philanthropy and Social Impact. In this newly created position, Professor Naidoo will lead the group’s efforts to reach the 2.5 billion people living with uncorrected poor vision through inclusive business and philanthropy.
Professor Naidoo most recently served as associate professor of Optometry at the University of KwaZulu-Natal (UKZN), is the former CEO of the Brien Holden Vision Institute, and is the former Africa Chair of the International Agency for the Prevention of Blindness. This year, Kovin was recognized by the American Academy of Optometry with the Carel C. Koch Memorial Medal Award for his outstanding contributions to the enhancement and development of relationships between optometry and other professions.
Do you believe that silicone hydrogel materials are generally a healthier option for your patients than hydrogel materials?
Your Interesting Case Photo Here in the Next Issue
Have you seen an interesting case lately? Would you like to share it with your colleagues? An image from that case could appear in Contact Lenses Today in the coming weeks!
We welcome photo submissions from our readers! It is easy to submit a photo for consideration for publishing in Contact Lenses Today. Simply visit http://www.cltoday.com/upload/upload.aspx to upload your image. Please include a detailed explanation of the photo and your full name, degree or title, and city/state/country.
SPECIALTY LENS SPACE
Karen DeLoss, OD
Which Is Better, One or Two?
There is certainly no shortage of myopia throughout the world. However, as eyecare providers, it is helpful to be well-versed in all treatment options and current clinical research. Within the arena of myopia control, there are several options. One avenue would be an optical correction, such as bifocal spectacles, multifocal contact lenses, or orthokeratology. The second avenue would be a pharmacological approach, such as low-dose atropine. As a clinician, I am often asked by my patients’ parents as to what is the best option for their child. To be honest, I am apt to go to my wheelhouse. Recently, however, I have found that it is best to present all of the options as well as to also underscore that all are off-label approaches.
The end goal with myopia control is to reduce progression and axial length.1 With respect to optical methods of myopia control, clinical studies have found that contact lenses and orthokeratology outweigh spectacles in terms of efficacy, particularly with increased compliance.2,3 The pharmacological route is mainly confined to atropine. Clinical studies of 0.01% atropine have shown significant change in spherical equivalent, but atropine fails to halt axial lengthening compared to control eyes.4,5 Higher concentrations of atropine raised concerns of side effects.6 While research supports the use of myopia control, long-term data is scarce, and further research is needed. Finally, it is important to educate patients on compliance, as potential rebound myopia can occur.
1. Brennan NA. Predicted reduction in high myopia for various degrees of myopia control. Contact Lens Anterior Eye. 2012 Dec 1;35:e14-e15.
2. Huang J, Wen D, Wang Q, et al. Efficacy comparison of 16 interventions for myopia control in children: a network meta-analysis. Ophthalmology. 2016 Apr;123:679-708.
3. Lam CS, Tang WC, Tse DY, Tang YY, To CH. Defocus incorporated soft contact (DISC) lens slows myopia progression in Hong Kong Chinese schoolchildren: a 2-year randomized clinical trial. Br J Ophthalmol. 2014 Jan;98:40-45.
4. Chia A, Chua WH, Cheung YB, et al. Atropine for the treatment of childhood myopia: safety and efficacy of 0.5%, 0.1% and 0.01% doses (Atropine for the treatment of Myopia 2). Ophthalmology. 2012 Feb;119:347-354.
5. Yam JC, Jiang Y, Tang SM, et al. Low-Concentration Atropine for Myopia Progression (LAMP) Study: a randomized, double-blinded, placebo controlled trial of 0.05%, 0.025%, and 0.01% atropine eye drops in myopia control. Ophthalmology. 2018. [In Press]
6. Brodstein RS, Brodstein DE, Olson RJ, et al. The treatment of myopia with atropine and bifocals. A long-term prospective study. Ophthalmology. 1984 Nov;91:1373-1379.
MATERIALS & DESIGNS
David L. Kading, OD
My Subscription for Great Compliance
Eyecare practitioners frequently talk about compliance rates with their material and design selections. The last thing that they want is for their patients to overwear their lenses and develop an infection or complication. They can speak to patients about the importance of lens replacement, but—as has been said before—a primary reason why patients do not replace their lenses is simply because they forget. Especially for frequent replacement lenses that are not daily disposable, replacement dates should be on their calendars or they should have a system to remember.
One additional reason why people fail to replace their lenses on time is because they run out. As business owners, eyecare practitioners are frequently working to improve their sales of annual supplies of lenses. This serves many purposes. Patients may think that practitioners are doing this so that they can make a larger sale. While that is a nice advantage, they are also doing it to reduce the number of transactions that they need to make throughout the year for lens sales; but, perhaps most importantly, they don’t want patients running out of their lenses. The fact remains that some patients simply will not purchase the entire year at once because of cost concerns.
In the last five years, practitioners have seen a surge of subscription services for all types of products (e.g., razor blades or vitamins). Patients are familiar with these services and how they can make their lives easier. These days, several services like this are in the eyecare space. Patients can now elect to have their lenses delivered to them while making either monthly or quarterly payments for their lenses. Although these services come at a slight premium, patients are familiar with that type of pricing model. For instance, you can pay for a year of many of these services for one flat fee, but if you elect to pay monthly, the cost is slightly more overall.
We have had several patients sign up for this type of service, and it puts us at ease. Practitioners know that their patients are not neglecting a year’s supply because they want to be noncompliant. Rather, they realize that it is a cost concern. By positioning this type of subscription service to them, physicians can help improve their patients’ compliance and success with any material or design. I subscribe to great compliance for my patients.
Detection of Lipid Mediators of Inflammation in the Human Tear Film
Lipid mediators of inflammation are a group of signaling molecules produced by various cells under physiological conditions that modulate the inflammatory process during various pathologic conditions. Although eicosanoids and F2-isoprostanes are recognized lipid mediators of inflammation, there is no consensus yet on the extraction and mass spectrometry (MS) method for their analysis in individual human tear samples. Thus, the aim of this study was to develop an optimal method for extraction of lipid mediators of inflammation in the tear film and to evaluate MS techniques for their analysis.
Basal tears were collected from each eye of 19 subjects using glass microcapillaries. Lipid extraction was performed using either varying concentrations of acidified methanol, a modified Folch method, or solid-phase extraction. Initially, an untargeted analysis of the extracts was performed using a SCIEX TripleTOF 5600 mass spectrometer to identify any lipid mediators of inflammation (eicosanoids); later, a targeted analysis was performed using the SCIEX 6500 Qtrap to identify and quantify prostaglandins and isoprostanes. Mass spectra and chromatograms were analyzed using Peakview, XCMS, and Multiquant software.
Prostaglandins and isoprostanes were observed and quantified using the Qtrap mass spectrometer under multiple reaction monitoring (MRM) mode after solid-phase extraction. Extraction with acidified methanol along with the Folch method produced cleaner spectra during MS with the Triple time of flight (TOF) mass spectrometer. Lipid mediators of inflammation were not observed in any of the tear samples using the Triple TOF mass spectrometer.
The researchers concluded that solid-phase extraction may be the method of choice for extraction of prostaglandins and isoprostanes in low volumes of tears. The SCIEX Qtrap 6500 in MRM mode may be suitable to identify and quantify similar lipid mediators of inflammation.
Panthi S, Chen J, Wilson L, Nichols JJ. Detection of Lipid Mediators of Inflammation in the Human Tear Film. Eye Contact Lens. 2018 Oct 5. [Epub ahead of print]